All news

Agios bulls and bears split on PYRUKYND growth

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Agios Pharmaceuticals shareholders have lost 22.2% over the past year, with analysts weighing PYRUKYND's expansion and revenue growth against persistent net losses. The stock trades at $34.16 versus a $40.75 average analyst target, implying 19.3% upside, and coverage stands at seven Buy, three Hold and zero Sell ratings. Investors face a profitability question despite the drug's European approval.

Read original source

AGIO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.